Scarica l'app Stockscreener
1.28
0.79%
0.01
Dopo l'orario di chiusura:
1.31
0.03
+2.34%
Precedente Chiudi:
$1.27
Aprire:
$1.25
Volume 24 ore:
21,200
Relative Volume:
0.06
Capitalizzazione di mercato:
$33.68M
Reddito:
$9.06M
Utile/perdita netta:
$-50.39M
Rapporto P/E:
-0.6667
EPS:
-1.92
Flusso di cassa netto:
$5.89M
1 W Prestazione:
+2.40%
1M Prestazione:
-5.88%
6M Prestazione:
-20.00%
1 anno Prestazione:
-51.52%
Intervallo 1D:
$1.25
$1.34
Intervallo di 1 settimana:
$1.21
$1.34
Portata 52W:
$0.8502
$2.787
Lava Therapeutics Nv Stock (LVTX) Company Profile
Nome
Lava Therapeutics Nv
Settore
Industria
Telefono
31 6 3000 3035
Indirizzo
YALELAAN 62, UTRECHT
Confronta LVTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.28 | 32.88M | 9.06M | -50.39M | 5.89M | -1.92 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-19 | Iniziato | JP Morgan | Overweight |
| 2021-04-19 | Iniziato | Jefferies | Buy |
| 2021-04-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Lava Therapeutics Nv Borsa (LVTX) Ultime notizie
LAVA Therapeutics NV reports results for the quarter ended March 31Earnings Summary - TradingView
LAVA Therapeutics (LVTX) Receives Reiterated Market Perform Rati - GuruFocus
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update - GlobeNewswire
LAVA (LVTX) Pursues Strategic Moves Amid Workforce Restructuring - GuruFocus
LAVA Therapeutics Slashes 30% Workforce, Closes Netherlands Operations Amid Strategic Review - Stock Titan
LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency - Nasdaq
Lava Therapeutics Granted Full Waiver For RVO Payment Obligation - marketscreener.com
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewswire
LAVA Therapeutics Strengthens Balance Sheet: Secures Complete Waiver of $5.1M Debt - Stock Titan
Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues - simplywall.st
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut - Investing.com India
LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright - Defense World
Leerink cuts Lava Therapeutics stock target to $1 By Investing.com - Investing.com Canada
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut By Investing.com - Investing.com South Africa
Leerink cuts Lava Therapeutics stock target to $1 - Investing.com
JMP maintains LAVA Therapeutics stock Market Perform rating By Investing.com - Investing.com Australia
JMP maintains LAVA Therapeutics stock Market Perform rating - Investing.com
Lava Therapeutics Reports 2024 Financial Results - TipRanks
LAVA Therapeutics NV earnings beat by $0.16, revenue topped estimates - Investing.com Australia
LAVA Therapeutics N.V. (LVTX) reports earnings - Quartz
LAVA Therapeutics NV SEC 10-K Report - TradingView
LAVA Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire
LAVA Therapeutics Q4 Basic EPS USD -0.14 - MarketScreener
LAVA Therapeutics Slashes Workforce 30% While Securing $12M in Big Pharma Milestone Payments - Stock Titan
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts By Investing.com - Investing.com South Africa
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts - Investing.com
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq
LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks
LAVA Announces Evaluation of Strategic Options - GlobeNewswire
Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan
LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia
LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
LAVA Therapeutics begins trial for cancer treatment - Investing.com India
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire
LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World
LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com
Lava Therapeutics Nv Azioni (LVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):